A Review of Current Clinical Trials for Improving Neurological Outcomes

Jha, Abhay K.; Lammertse, Daniel P.; Charlifue, Susan; Clayton, Gerald

doi:10.1310/bqey-hlem-yypv-ce46

Search citation statements

Order By: Relevance

Paper Sections

Select...

Nerve Regeneration2

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2011

Publication Types

Select...

Book1

Other1

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Upon activation, Rho binds to Rho kinase (ROCK), an important regulator of axonal growth and cellular apoptosis. The protein will be available as a kit, in combination with a fibrin sealant, under the commercial name of Cethrin Ò [72,73]. By blocking Rho, the intention is that nerve cells will be able to repair themselves and regrow.…”

Section: Nerve Regenerationmentioning

confidence: 99%

“…The recombinant version of C3 is extended with a peptide transport signal, to enhance cellular permeability [71]. A Phase I/IIa multicenter clinical trial was initiated in 2005 [73], for a single dose application of Cethrin Ò to the dura mater at the time of spinal decompression (within seven days of injury) in complete spinal cord injuries from T2 to T12 and C4 to T1. The protein will be available as a kit, in combination with a fibrin sealant, under the commercial name of Cethrin Ò [72,73].…”

Section: Nerve Regenerationmentioning

confidence: 99%

See 1 more Smart Citation